Search in:

Advanced search

Diabetes, Metabolic Syndrome and Obesity Volume 8, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements

Fred Yang1 AstraZeneca, Gaithersburg, MD, USACorrespondence[email protected]

Murray Stewart2 GlaxoSmithKline, Upper Merion, PA, USA

June Ye2 GlaxoSmithKline, Upper Merion, PA, USA

David DeMets3 Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison, WI, USA

Pages 315-325 | Published online: 20 Jul 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

DormandyJACharbonnelBEcklandDJPROactive investigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet20053661279 128916214598
PubMed Web of Science ®Google Scholar
PatelAChalmersJPoulterNADVANCE: action in diabetes and vascular diseaseJ Hum Hypertens200519Suppl 1S27 S3216075030
PubMed Web of Science ®Google Scholar
PatelAADVANCE Collaborative GroupMacMahonSChalmersJEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet20073709590829 84017765963
PubMed Web of Science ®Google Scholar
VibertiGLachinJHolmanRADOPT Study GroupA Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and EuropeDiabet Med200623121289 129417116177
PubMed Web of Science ®Google Scholar
DuckworthWAbrairaCMoritzTVADT InvestigatorsGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med20093602129 13919092145
PubMed Web of Science ®Google Scholar
MeyersCDMcCarrenMWongNDAbrairaCDuckworthWCKashyapMLVADT InvestigatorsBaseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial)Am J Cardiol200698163 6516784922
PubMed Web of Science ®Google Scholar
ACCORD Study GroupBuseJBBiggerJTAction to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methodsAm J Cardiol20079912A21i 33i
Web of Science ®Google Scholar
HomePDPocockSJBeck-NielsenHRECORD Study TeamRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet200937396812125 213519501900
PubMed Web of Science ®Google Scholar
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study GroupBaseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialAm Heart J20081563528 53618760137
PubMed Web of Science ®Google Scholar
BARI 2D Study GroupFryeRLAugustPA randomized trial of therapies for type 2 diabetes and coronary artery diseaseN Engl J Med2009360242503 251519502645
PubMed Web of Science ®Google Scholar
WhiteWBBakrisGLBergenstalRMEXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeAm Heart J20111624620 62621982652
PubMed Web of Science ®Google Scholar
WhiteWBCannonCPHellerSREXAMINE InvestigatorsAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med20133691327 133523992602
PubMed Web of Science ®Google Scholar
SciricaBMBhattDLBraunwaldESAVOR-TIMI 53 Steering Committee and InvestigatorsSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317 132623992601
PubMed Web of Science ®Google Scholar
SciricaBMBhattDLBraunwaldEThe design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 studyAm Heart J20111625818 82522093196
PubMed Web of Science ®Google Scholar
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 DiabetesSilver SpringUS Food and Drug Administration2008
Google Scholar

References

DanaeiGFinucaneMMLuYGlobal Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose)National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsLancet2011378978531 4021705069
PubMed Web of Science ®Google Scholar
Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF ConsultationWorld Health Organization; International Diabetes Federation2006 Available from: http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf?ua=1Accessed January 31, 2015
Google Scholar
National Diabetes Statistics Report, 2014: Estimates of Diabetes and Its Burden in the United StatesDivision of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdfAccessed December 31, 2014
Google Scholar
BrassEPThe Food and Drug Administration and the future of drug development for the treatment of diabetesDiabetes Spectr201427275 77
Google Scholar
FlemingTRIdentifying and addressing safety signals in clinical trials: some issues and challengesFlemingTRWeirBSProceedings of the Fourth Seattle Symposium in Biostatistics: Clinical TrialsNew York, NYSpringer2013137 156
Google Scholar
Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 DiabetesUS Department of Health and Human Services, Food and Drug Admin istration, Center for Drug Evaluation and Research (CDER)2008 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregu-latoryinformation/guidances/ucm071627.pdfAccessed January 31, 2012
Google Scholar
DormandyJACharbonnelBEcklandDJPROactive investigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet20053661279 128916214598
PubMed Web of Science ®Google Scholar
PatelAChalmersJPoulterNADVANCE: action in diabetes and vascular diseaseJ Hum Hypertens200519Suppl 1S27 S3216075030
PubMed Web of Science ®Google Scholar
PatelAADVANCE Collaborative GroupMacMahonSChalmersJEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet20073709590829 84017765963
PubMed Web of Science ®Google Scholar
VibertiGLachinJHolmanRADOPT Study GroupA Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and EuropeDiabet Med200623121289 129417116177
PubMed Web of Science ®Google Scholar
DuckworthWAbrairaCMoritzTVADT InvestigatorsGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med20093602129 13919092145
PubMed Web of Science ®Google Scholar
MeyersCDMcCarrenMWongNDAbrairaCDuckworthWCKashyapMLVADT InvestigatorsBaseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial)Am J Cardiol200698163 6516784922
PubMed Web of Science ®Google Scholar
ACCORD Study GroupBuseJBBiggerJTAction to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methodsAm J Cardiol20079912A21i 33i
Web of Science ®Google Scholar
HomePDPocockSJBeck-NielsenHRECORD Study TeamRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet200937396812125 213519501900
PubMed Web of Science ®Google Scholar
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study GroupBaseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialAm Heart J20081563528 53618760137
PubMed Web of Science ®Google Scholar
BARI 2D Study GroupFryeRLAugustPA randomized trial of therapies for type 2 diabetes and coronary artery diseaseN Engl J Med2009360242503 251519502645
PubMed Web of Science ®Google Scholar
WhiteWBBakrisGLBergenstalRMEXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeAm Heart J20111624620 62621982652
PubMed Web of Science ®Google Scholar
WhiteWBCannonCPHellerSREXAMINE InvestigatorsAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med20133691327 133523992602
PubMed Web of Science ®Google Scholar
SciricaBMBhattDLBraunwaldESAVOR-TIMI 53 Steering Committee and InvestigatorsSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317 132623992601
PubMed Web of Science ®Google Scholar
SciricaBMBhattDLBraunwaldEThe design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 studyAm Heart J20111625818 82522093196
PubMed Web of Science ®Google Scholar
Eli Lilly and CompanyResearching cardiovascular events with a weekly incretin in diabetes (REWIND) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01394952. NLM identifier: NCT01394952Accessed June 30, 2014
Google Scholar
AstraZenecaExenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus Available from: https://clinicaltrials.gov/ct2/show/NCT01144338. NLM identifier: NCT01144338Accessed October 24, 2011
Google Scholar
Boehringer IngelheimCAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes Available from: http://www.clinicaltrials.gov/ct2/show/NCT01243424. NLM identifier: NCT01243424Accessed June 30, 2014
Google Scholar
Boehringer IngelheimCardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01897532. NLM identifier: NCT01897532Accessed June 30, 2014
Google Scholar
Novo Nordisk A/SLiraglutide effect and action in diabetes: evaluation of cardiovascular outcome results – a long term evaluation (LEADER^®) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=NCT01179048&rank=1. NLM identifier: NCT01179048Accessed October 25, 2011
Google Scholar
SanofiEvaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01147250. NLM identifier: NCT01147250Accessed June 30, 2014
Google Scholar
Merck Sharp & Dohme CorpSitagliptin cardiovascular outcome study (MK-0431-082) (TECOS) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00790205. NLM identifier: NCT00790205Accessed June 30, 2014
Google Scholar
BadimonLHernández VeraRVilahurGDeterminants of cardiovascular risk in diabetes beyond hyperglycemiaJ Cardiovasc Dis20131253 62
Google Scholar
BaronJASandlerRSBresalierRSCardiovascular events associated with rofecoxib: final analysis of the APPROVe trialLancet200837296511756 176418922570
PubMed Web of Science ®Google Scholar
BresalierRSSandlerRSQuanHAdenomatous Polyp Prevention on Vioxx (APPROVe) Trial InvestigatorsCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med2005352111092 110215713943
PubMed Web of Science ®Google Scholar
AklEABrielMYouJJPotential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic reviewBMJ2012344e280922611167
PubMed Web of Science ®Google Scholar
HungHMWangSJSome controversial multiple testing problems in regulatory applicationsJ Biopharm Stat20091911 1119127460
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date